Immunome Inc. — Director's Dealing 2020

Oct 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-06

Reporting Person: Lefenfeld Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	C	22222	—	Acquired	22222	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Series A Convertible Preferred Stock	$	C	22222	Disposed		Common Stock (22222)	Direct
2020-10-06	Warrant (right to buy)	$9.00	C	11111	Disposed	2023-06-02	Series A Convertible Preferred Stock (11111)	Direct
2020-10-06	Warrant (right to buy)	$9.00	C	11111	Acquired	2023-06-02	Common Stock (11111)	Direct

Footnotes

F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the
Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F2: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the
closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.

F3: Immediately exercisable.